| Literature DB >> 33455532 |
Qing Wang1, Ning Liu1, Yuan-Shu Ni1, Jia-Mei Yang1, Lin Ma2, Xiao-Bing Lan1, Jing Wu3, Jian-Guo Niu2, Jian-Qiang Yu1,4.
Abstract
Ischemic stroke has a high lethality rate worldwide, and novel treatments are limited. Calcium overload is considered to be one of the mechanisms of cerebral ischemia. Transient receptor potential melastatin 2 (TRPM2) is a reactive oxygen species (ROS)-sensitive calcium channel. Cerebral ischemia-induced TRPM2 activation triggers abnormal intracellular Ca2+ accumulation and cell death, which in turn causes irreversible brain damage. Thus, TRPM2 has emerged as a new therapeutic target for ischemic stroke. This review provides data on the expression, structure, and function of TRPM2 and illustrates its cellular and molecular mechanisms in ischemic stroke. Natural and synthetic TRPM2 inhibitors (both specific and nonspecific) are also summarized. The three-dimensional protein structure of TRPM2 has been identified, and we speculate that molecular simulation techniques will be essential for developing new drugs that block TRPM2 channels. These insights about TRPM2 may be the key to find potent therapeutic approaches for the treatment of ischemic stroke.Entities:
Keywords: TRPM2 blockers; TRPM2 channel; ischemic stroke; pathogenesis; virtual screening
Mesh:
Substances:
Year: 2021 PMID: 33455532 PMCID: PMC7833771 DOI: 10.1080/19336950.2020.1870088
Source DB: PubMed Journal: Channels (Austin) ISSN: 1933-6950 Impact factor: 2.581